| ||
Is Sun Pharma getting back on the acquisition track? Livemint At first sight, Sun Pharmaceutical Industries Ltd's sales guidance for 2012-13 appears conservative compared with its performance last fiscal. The company's sales in 2011-12 grew by 40% to Rs8,006 crore, and it expects sales to grow by 18-20%. See all stories on this topic » | ||
Pharma sector likely to grow at 15.3% CAGR Hindu Business Line PTI Growth rate for the Indian pharmaceutical market is set to rise over medium-term, according to a research report. The CAGR (compound annual growth rate) over the past three years had been 12.4 per cent, but it is expected to be up at 15.3 per cent ... See all stories on this topic » | ||
| ||
| ||
ASCO Presentations Highlight Preliminary Results of Studies with MLN9708 ... MarketWatch (press release) CAMBRIDGE, Mass., Jun 03, 2012 (BUSINESS WIRE) -- Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported phase 1 and phase 1/2 preliminary results from three studies evaluating the safety, ... See all stories on this topic » | ||
Teva's Treanda Delays Tumor Growth Bloomberg Teva Pharmaceutical Industries Ltd. (TEVA)'s Treanda worked better than a standard therapy and with fewer side effects to slow the growth of immune system tumors, a finding that could push more doctors to prescribe the drug as an initial treatment. See all stories on this topic » | ||
In Euro Zone, The Coming Crisis of People's Health Forbes The pharmaceutical giant Roche has decided to set a ceiling on the orders that 11 Spanish hospitals will be allowed to place until they settle at least part of their ballooning unpaid bills. One more center, the Hospital Provincial de Castellón, ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment